ACTRN12613000652774
Not yet recruiting
Not Applicable
Efficacy of intranasal fentanyl for the treatment of moderate to severe pain in adult patients in the emergency department
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Peninsula Health
- Enrollment
- 150
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age greater or equal to 18 years
- •Self\-report pain severity as being greater than or equal to 6 on the standard 11\-point verbal rating scale, where 0 is no pain and 10 is the worst pain imaginable
- •Medical recommendation for parenteral analgesia (attending doctor’s discretion)
- •Pain from any cause other than the specific exclusion criteria (see below)
Exclusion Criteria
- •Known allergy or previous adverse reaction to fentanyl
- •Use of oral, intranasal or parenteral narcotic analgesia in previous 4 hours (either pre\-hospital or in the emergency department) \[NB. Pre\-hospital use of short\-acting inhaled methoxyfluorane alone or non\-narcotic analgesics do not constitute an exclusion]
- •MAO Inhibitor antidepressant use within last 14 days
- •Haemodynamic instability (eg HR \> 120/min or BP \< 90 mmHg) with the need for time critical interventions of any type
- •Suspicion of any of the following medical conditions:
- •myocardial ischaemia (concern re transient hypotension from fentanyl)
- •suspected subarachnoid haemorrhage (concern re transient hypotension from fentanyl)
- •migraine (specific proven therapy)
- •Relative contraindication to, or anticipated difficulty with nasal administration of medication that may prevent adequate administration or absorption of intranasal medication (eg aberrant nasal anatomy, acute or chronic nasal problems or nasal trauma).
- •Presence of acute cognitive impairment (any underlying cause)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
The efficacy of intranasal fentanyl as an adjunct for pain management in retinopathy of prematurity screeningEfficacy of intranasal fentanyl drops as an adjunct for pain management in retinopathy of prematurity screening.Pain, retinopathy of prematurity, intranasal fentanylTCTR20230109003Bhumibol Adulyadej Hospital49
Not yet recruiting
Phase 3
Intranasal fentanyl for analgesia during non-emergent intubation in neonatesCTRI/2024/02/063361Dr Vivek S
Completed
Phase 2
The Use of Intranasal Fentanyl for the Treatment of Incident Dyspnea in Congestive Heart Failure: A Prospective TrialDyspneaCongestive Heart FailureNCT02454751St. Boniface Hospital8
Completed
Not Applicable
Effect of Nasal fentanyl in patients with cataract surgeryIRCT20200605047662N1Esfahan University of Medical Sciences90
Not yet recruiting
Phase 4
Intranasal fentanyl as add-on therapy in screening of retinopathy of prematurity - to reduce the pain associate with rop screeningHealth Condition 1: H36- Retinal disorders in diseases classified elsewhereCTRI/2023/07/055556DR SANDIP KUMAR SAH